TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB

Abstract:

Compositions and methods are described for the delivery of a fully human post-translaionally modified (HuPTM) monoclonal antibody ("mAh") or the antigen-binding fragment of a mAh against human vascular endothelial growth factor ("hVEGF")--such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment--to the retina/vitreal humour in the eye(s) of human subjects diagnosed with diabetic retinopathy.